VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ROIV
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ROIVRoivant Sciences Ltd.
$38.71$28.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ROIV logo

Roivant Sciences Ltd.

ROIV
NASDAQ · Immunology Biotech
$38.71
At close - Nov 17, 4:00 PM EST - USD
Market Cap$27.96B
P/E-81.3x
52W High$42.50
Volume8.41M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Cash Runway Dependence Overshadows Pipeline Optionality at Roivant

Roivant's reported figures suggest a company still in a heavy investment phase, with quarterly operating losses ranging from roughly -$102M to -$366M and revenue only $1.4M to $35.1M in recent quarters, leaving gross profit far too small to absorb R&D and SG&A that run near $145M to $203M each per quarter.

GrowthDecelerating
ProfitabilityNegative
ValuationReview
TechnicalsStrong
Explore valuation models
MARKET ACTION

ROIV price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

8/12 Beats

EPS beat 8 of last 12 quarters

02

Valuation risk

-327% Peers

P/E is 327% below peer median

03

Market leadership

RS 92 · Leader

High momentum (Outperforming 92% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Feb 9
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue has been lumpy, reaching $35.1M in 2026Q2 after $1.4M in 2026Q1, yet operating margin remained deeply negative at -7.6% in the latest quarter and -253.8% the prior quarter, indicating fixed operating costs still overwhelm gross profit.

Analyst Consensus+27.9% target
Buy(16 analysts)
14 Buy2 Hold0 Sell

The Bull Case

Upside Catalysts

Brepocitinib Program Expansion

Roivant Sciences is expanding its brepocitinib development program with a new Phase 2b/3 trial in Lichen Planopilaris (LPP), indicating potential growth in its pipeline.

FDA Priority Review for Brepocitinib

The U.S. FDA has accepted Roivant's New Drug Application for brepocitinib in dermatomyositis and granted Priority Review, targeting a potential launch by Q3 2026.

Phase 3 Batoclimab Data Update

Positive Phase 3 study results for batoclimab in Thyroid Eye Disease (TED) could drive investor confidence and future revenue streams.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ROIV+76.52%
S&P 500 (^GSPC)+7.21%
1-Year Return
ROIV+88.28%
S&P 500 (^GSPC)+10.03%
3-Year Return
ROIV+331.55%
S&P 500 (^GSPC)+64.32%
5-Year Return
ROIV+375.55%
S&P 500 (^GSPC)+58.41%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
-81.3x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-81.3x
2.0x
0th· Low
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$1.86-95.2%
Base (Fair)$34.86-11.8%
Bull$1.90-95.1%
$1.86 Bear$34.86 Base$1.90 Bull
Current Market Price: $38.71
Trades at a 11.0% premium to Base DCF ($34.86)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$8M-71.6% YoY
Net income FY25
-$300M-74.3% YoY
Free cash flow FY25
-$759M+10.1% YoY
Operating margin FY25
-15560.6%-11727.3 pts YoY
ROIC (FY25)-29.4%
Avg ROIC 5Y-146.9%
ROE (TTM)-7%
Piotroski Score1 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate8/12 (67%)
Revenue Beat Rate4/12 (33%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 9, 2026
-$0.27+26.4%
vs -$0.37
$35M+710.0%
vs $4M
Q3 2026
Aug 6, 2026
-$0.33-10.1%
vs -$0.30
$1M-29.9%
vs $2M
Q2 2026
May 20, 2026
-$0.28+3.5%
vs -$0.29
$3M-26.2%
vs $3M
Q1 2026
Feb 6, 2026
-$0.24+19.9%
vs -$0.30
$2M-60.6%
vs $5M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·1d ago
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha·Nov 11, 2026
Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum

Roivant Sciences Ltd. remains a Buy as its diversified "-vant" model delivers multiple blockbuster pipeline opportunities and robust cash reserves. Immunovant's IMVT-1402 shows superior efficacy in rheumatoid arthritis, but regulatory and translational hurdles remain for broader adoption. Priovant's LISRAYA launches in dermatomyositis, with promising Phase 3 data in non-infectious uveitis, while Pulmovant's mosliciguat demonstrates best-in-class Phase 2 results in PH-ILD.

GlobeNewsWire·Nov 10, 2026
Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology

DURHAM, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced the publication in  JAMA Dermatology of results from the Phase 2 portion of the BEACON study, a randomized, double-blind, placebo-controlled trial evaluating oral brepocitinib in adults with cutaneous sarcoidosis (CS). The publication describes improvements in skin disease activity and skin-related quality of life over 16 weeks of treatment, with 69.2% of participants receiving brepocitinib 45 mg once daily achieving “Clear” or “Almost Clear” skin with at least a 2-category improvement, compared with none of the participants receiving placebo (P = 0.0047).

Defense World·Nov 10, 2026
Roivant Sciences Ltd. $ROIV Stock: CenterBook Partners LP Cuts Position

CenterBook Partners LP decreased its stake in Roivant Sciences Ltd. (NASDAQ: ROIV) by 35.6% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,188 shares of the company's stock after selling 18,928 shares during the period. CenterBook Partners LP's holdings in

Filtered for Roivant Sciences Ltd.More Headlines
04

Compare before deciding

Benchmark ROIV against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Roivant Sciences Ltd. (ROIV)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ROIV logoROIVRoivant Sciences Ltd.Current
$38.71$27.96B-81.26-71.57%-838.19%-6.96%—
BHVN logoBHVNBiohaven Ltd.
$13.24$1.99B-3.69——-2271.87%—
IMVT logoIMVTImmunovant, Inc.
$33.21$6.85B-13.49—-7173.52%-63.01%—
KYMR logoKYMRKymera Therapeutics, Inc.
$121.52$10B-34.81-16.72%-341.87%-22.39%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$305.06$8.5B-24.77-100%—-29.41%—
ABBV logoABBVAbbVie Inc.
$292.86$517.42B50.148.57%15.68%—2.24%

Compare ROIV vs Peers

Roivant Sciences Ltd. (ROIV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs BHVN

Most directly comparable listed peer for ROIV.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare ROIV against a more recognizable public peer.

Peer Set

Compare Top 5

vs BHVN, IMVT, KYMR, PRAX

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

ROIV SEC Filings & Documents

Roivant Sciences Ltd. (ROIV) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 9, 2026·SEC

Material company update

Oct 21, 2026·SEC

Material company update

Aug 6, 2026·SEC

10-K Annual Reports

2
FY 2026

May 20, 2026·SEC

FY 2025

May 29, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 9, 2026·SEC

FY 2026

Aug 6, 2026·SEC

FY 2026

Feb 6, 2026·SEC

Get notified when ROIV posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ROIV Frequently Asked Questions

Roivant Sciences Ltd. (ROIV) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Roivant Sciences Ltd.'s revenue?

Roivant Sciences Ltd. (ROIV) reported $41.1M in revenue over the trailing twelve months. Revenue was $8.3M in fiscal year 2025. That is 88% less than the $67.7M of fiscal year 2019.

How fast is Roivant Sciences Ltd. growing?

Roivant Sciences Ltd. (ROIV) grew revenue by 102.1% over the trailing twelve months, compared with the twelve months before.

Is ROIV profitable?

No. Roivant Sciences Ltd. (ROIV) reported a net loss of $344.3M over the trailing twelve months.

Dividend & Returns
What is ROIV's return on equity?

Roivant Sciences Ltd. (ROIV) had a return on equity (ROE) of -7.0% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Roivant Sciences Ltd.'s free cash flow?

Roivant Sciences Ltd. (ROIV) had negative free cash flow of $26.2M over the trailing twelve months.

What if you invested $1,000 in ROIV back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →